Hemostatic Alternative

Medafor, Inc., a developer of advanced hemostasis and wound managementtechnology, recently announced that it has signed an exclusive, multi-yearagreement with Abbott Laboratories for the distribution of HemaBlock "Stopthe Bleed" to the veterinary market in the United States and worldwide.HemaBlock is a microporous, polysaccharide powder hemostat based on Medafor'spatented microsphere technology. HemaBlock will be marketed to veterinariansfor surgical, dental and critical care applications, providing a breakthroughhemostatic alternative which may result in faster procedural completiontimes and less discomfort for the patient versus current methods of hemostasis,the company says.

For fastest response call (847) 937-6100 or visit the Web site at